GlassScriptPhysician profile
Barbara Kerby
NPI 1326264953
$1,831.87
in general payments reported to CMS, 2019-2025
20 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $374 · 2023: $348 · 2024: $291 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $318.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $259.69 | 2021-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $197.03 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $181.46 | 2021-2025 | Shingrix, Arexvy, Boostrix |
| Novo Nordisk INC | $165.21 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $146.37 | 2022-2023 | |
| Abbvie INC. | $118.60 | 2022-2025 | |
| Esperion Therapeutics, INC. | $87.33 | 2021-2025 | Nexletol |
| Pfizer INC. | $79.16 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.46 | 2022-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $43.45 | 2022-2023 | Breztri |
| Idorsia Pharmaceuticals US INC | $27.69 | 2024 | Quviviq |
| Exact Sciences Corporation | $27.47 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $27.28 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $23.50 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $18.75 | 2021 | |
| Mylan Specialty L.P. | $18.33 | 2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $16.58 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2023 | Livalo |
| Pbg Puerto Rico LLC | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Kerby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.